FOLFIRINOX / mFOLFIRINOX
FOLFIRINOX is a four-drug chemotherapy combination that, in 2011, became the first treatment to meaningfully extend life in metastatic pancreatic cancer; it is now the standard before and after surgery.
Oxaliplatin, irinotecan, leucovorin, and 5-fluorouracil. PRODIGE 4/ACCORD 11 (2011): OS 11.1 vs 6.8 months versus gemcitabine in fit metastatic patients. Modified FOLFIRINOX (PRODIGE 24, 2018) became the adjuvant standard after resection with median OS ~54 months, and is the most used neoadjuvant regimen for borderline-resectable disease. Toxicity (neutropenia, diarrhoea, neuropathy) restricts it to ECOG 0-1 patients. NALIRIFOX (liposomal irinotecan) is a 2024 variant for metastatic disease.
Approvals
| Region | Year | Indication |
|---|---|---|
| Global | 2011 | Metastatic PDAC (PRODIGE 4 / ACCORD 11; component drugs generic) |
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials in OnCo
Latest papers
topQuery for this drug: (TITLE:"FOLFIRINOX / mFOLFIRINOX" OR ABSTRACT:"FOLFIRINOX / mFOLFIRINOX") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FOLFIRINOX / mFOLFIRINOX, not a curated reading list.